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Context: Patients with Addison’s disease reproducibly self-report impairment in specific dimen-
sions of general well-being questionnaires, suggesting particular deficiencies in health-related
quality-of-life (HRQoL).
Objective:We sought to develop anAddison’s disease-specific questionnaire (AddiQoL) that could
better quantify altered well-being and treatment effects.
Design, Setting, Patients, Intervention, and Outcomes: We reviewed the literature to identify
HRQoL issues in Addison’s disease and interviewed patients and their partners in-depth to explore
various symptomdomains. A list of itemswas generated, and nine expert clinicians and five expert
patients assessed the list for impact and clarity. A preliminary questionnaire was presented to 100
Addison’s outpatients; the number of items was reduced after analysis of the distribution of the
responses. The final questionnaire responses were assessed by Cronbach’s  and Rasch analysis.
Results and Interpretation: Published studies of HRQoL in Addison’s disease indicated reduced
vitality and general health perception and limitations in physical and emotional functioning.
In-depth interviews of 14 patients and seven partners emphasized the impact of the disease on the
emotional domain. Seventy HRQoL items were generated; after the expert consultation process
and pretesting in 100 patients, the number of items was reduced to 36. Eighty-six patients com-
pleted the final questionnaire; the responses showed high internal consistency with Cronbach’s 
0.95 and Person Separation Index 0.94 (Rasch analysis).
Conclusions: We envisage AddiQoL having utility in trials of hormone replacement and manage-
ment of patients with Addison’s disease, analogous to similar questionnaires in GH deficiency
(AGHDA) and acromegaly (AcroQoL). (J Clin Endocrinol Metab 95: 545–551, 2010)
Primary adrenal insufficiency (Addison’s disease) isconventionally treated with glucocorticoid and
mineralocorticoid replacement (1), and more recently,
replacement of the adrenal androgen dehydroepiandro-
sterone (DHEA) has beenmuch investigated (2–5).How-
ever, the current replacement regimens do not reproduce
the normal diurnal variations of the glucocorticoid levels,
with uncertain consequences for patients’ health (6).
Novel treatment strategies such as modified-release hy-
drocortisone tablets or continuous sc hydrocortisone in-
fusion have been proposed (7, 8). There is no “gold-stan-
dard” for assessment of treatments, but a clinical scoring
system has been proposed (9). Circulating hormone levels
do not necessarily reflect the cellular effects of these hor-
mones. Measurement of cortisol profiles can guide glu-
cocorticoid replacement therapy (10–13), whereas min-
eralocorticoid therapy is monitored by measurement of
biomarkers of responses such as electrolyte levels, blood
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pressure, and plasma renin activity (1). DHEA replace-
ment therapy is assessed bymeasurement ofDHEAsulfate
and androgen levels, or possibly their metabolites (14).
Evenwith biochemically optimal replacement regimens, pa-
tients reproducibly self-report impairment in particular di-
mensions of general well-being questionnaires (5, 15–17).
Amultitudeof general questionnaires thatmeasure var-
ious dimensions of functioning and subjective well-being
exist; they are not specific to anypopulationordisease and
are thus particularly apt for large-scale population-based
observational studies, allowing comparisons across groups
and conditions. Disease-specific or, more precisely, disease-
sensitive questionnaires address symptom domains that are
relevant to a particular disease and potentially more able to
detect changes over time. Instruments that specifically mea-
sure particular symptoms are needed in endocrine disorders,
as illustrated by the development of disease-specific health-
related quality of life (HRQoL) questionnaires for the as-
sessment of other endocrine disorders such asGHdeficiency
[Assessment of Growth Hormone Deficiency in Adults
(AGHDA)] (18), acromegaly [Acromegaly Quality of Life
(AcroQoL) questionnaire] (19), and Cushing’s syndrome
(CushingQoL) (20).
Here, we describe the development of a novel disease-
specific HRQoL questionnaire (AddiQoL) for assessment
of Addison’s disease patients during replacement therapy.
Subjects and Methods
Design
We followed guidelines for development of disease-specific
questionnaires as described by Juniper et al. (21), as shown in
Fig. 1. The process may be divided into four stages: 1) identifi-
cationofHRQoL issues, i.e. literature reviewand interview stud-
ies; 2)HRQoL itemgeneration; 3)pretestingof thequestionnaire
in a patient cohort; and 4) field testing of the questionnaire.
The study was approved by the Cambridge Research Ethics
Committee, and all subjects gave written informed consent be-
fore participation.
Stage 1: literature review and in-depth interviews
An extensive search of the PubMed and PsychINFO data-
bases was undertakenwith the primary search terms “Addison’s
disease,” “adrenal insufficiency,” and “quality of life.” The ar-
ticles thus identified were further scrutinized for relevant refer-
ences. Patient surveys undertaken by Addison’s disease associ-
ations in different countries were obtained via the internet or
by personal contact. Surveys using validated questionnaires
and surveys using nonvalidated questionnaires were analyzed
separately.
Outpatientswith verifiedAddison’s disease (n14) and their
partners (n 7) were invited to participate in an in-depth inter-
view aimed at identifying previously neglected HRQoL issues
and to describe their relative importance. Inclusion of patients
sought to represent a range of age, gender and disease duration;
the inclusion stoppedas successive interviews ceased to yieldnew
information relevant to the research objective, yielding a sample
size typical for in-depth interview studies. Patients with well-
controlled concomitant hypothyroidism were also included. In-
sulin-treated diabetes mellitus or other severe comorbidities ex-
cluded participation.
The interviews beganwith open-ended questions like: “What
is it like to live with Addison’s disease?” and “Is there anything
you would like to do that you cannot do because of Addison’s
disease?” The second part of the interview was semistructured,
with questions about issues anticipated to be relevant to the
patient. Their partners were interviewed in a similar way and
questioned about the impact of the disease on the family. The
interviews were carried out in the Wellcome Trust Clinical Re-
search Facility at Addenbrooke’s Hospital (Cambridge, UK) by
an endocrinologist (K.L.) unfamiliar with the study subjects and
an endocrine specialist nurse (S.C.). The interviews were taped,
and transcripts were analyzed by the Atlas.ti software (Atlas.ti
Scientific Software Development GmbH, Berlin, Germany) and
interpreted by qualitative research methods (22).
Stage 2: HRQoL item generation
Based on the literature review and the in-depth interview
data, 70 HRQoL items were generated to cover the relevant
issues with both positive and negative phrasings. Thirty-six
phrasings were adapted from existing questionnaires, and 34
were invented. Nine European expert endocrinologists and five
expert patients recruited from theUKAddison’s disease self-help
group assessed each item for frequency, importance, and clarity
of expression.
FIG. 1. Flow chart of study design.
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Stage 3: pretesting of the questionnaire in a
patient cohort (item reduction)
The preliminary questionnaire was pretested in a group of
100 anonymized patients with Addison’s disease, recruited from
the UK Addison’s disease self-help group; only patients with
primary adrenal insufficiency treated with fludrocortisone and
hydrocortisone were invited to participate. Patients with well-
controlled concomitant hypothyroidism were included; insulin-
treated diabetes mellitus or severe diseases such as cancer or
inflammatory diseases treated with glucocorticoids precluded
participation. The patients returned questionnaires without per-
sonal identification, indicating only age group and gender, as
shown in Table 1. Their responses to each item were scored on
a five-point Likert scale with scores ranging from 1 (strongly
disagree) to 5 (strongly agree), or 1 (almost never) to 5 (almost
all the time). For statistical analysis, the scores for the negatively
phrased items were reversed, rendering higher scores favorable.
The process whereby items were further reduced was based
on both statistical analysis and clinical considerations. First, the
distribution of the responses to each item was analyzed. Items
were discarded if the distribution of responseswas either narrow
or highly skewed towardhigher scores, indicating little relevance
or inappropriate wording of that item. Second, when two items
correlated significantly with Spearman’s R above 0.7, one of
them was discarded. Third, Cronbach’s  was calculated to as-
sess internal consistency of the selected items. The final selection
of items was made to ensure breadth of coverage and to include
items that were most likely to respond to treatment changes.
Stage 4: field testing of the final questionnaire
We selected the six-point scale 1 (none of the time)—6 (all of
the time) to indicate frequency, and 1 (strongly disagree)—6
(strongly agree) to indicate severity. The final 36-item question-
naire was sent to the 100 patients above for determination of
reliability and for initial analysis of dimensional structure, ap-
plying Rasch analysis (RUMM2020 software, Rasch Unidimen-
sional measurement models; RUMM Laboratories, Perth, WA,
Australia), as described in Statistics.
Statistics
For the pretest, the distributions of the responses to each item
were analyzed by descriptive statistics. When two items corre-
lated significantly (P 0.01) and with Spearman’s R above 0.7
(pair-wise correlation of all items), one of them was omitted.
Internal consistency was evaluated by Cronbach’s  and by the
Person Separation Index given by the Rasch analysis.
The Rasch model is an item response theory that can be used
to assess whether a group of items measure the same HRQoL
dimension (unidimensional construct). The Rasch model allows
quantitative assessment fromdata that are originally ordinal but
notnecessarily linear (additive), basedon logistic transformation
of the item responses (23). Within the mathematic model of
Rasch analysis, the items and the persons are organized in an
ordered hierarchy in which the item location represents item
difficulty, or the level of HRQoL impairment targeted by the
item. Item difficulty is calculated from the proportion of the
patient sample that endorsed each item. The person location
represents person ability or the patient’s level of HRQoL im-
pairment. Person ability is estimated from the proportion of
items that eachpersonendorsed.Byplacingbothmeasureson the
same scale, the Rasch analysis makes it possible to explore how
well the items are targeted for the sample population. The
RUMMsoftware calculates residual fit statistics for each person
andeach item,applying2 statistics for item-trait test-of-fit to the
TABLE 1. Age and sex distribution of the patients
Age range (yr)
Total<30 30–40 40–50 50–60 60–70 70 Unknown
Males 1 4 9 8 8 2 1 33
Females 3 9 16 23 9 4 3 67
Total 4 13 25 31 17 6 4 100
Data represent number of patients.
TABLE 2. Published mean scores in HRQoL studies applying the generic questionnaires SF-36 or GHQ in Addison’s
disease cohorts in Norway (15), United Kingdom (3, 5), and Germany (16, 25)
HRQoL domain Scale Score Normative
General health Vitality (SF-36) 47–52a 58–60
General health (SF-36) 56–59a 71–77
Self-esteem (GHQ) 8.1b 7.6
Coping (GHQ) 10.3 9.8
Physical health Role-physical (SF-36) 46–66a 78–87
Physical functioning (SF-36) PF 80–84 87–88
Bodily pain (SF-36) BP 76–79 75–79
Mental health Role-emotional (SF-36) 57–75a 82–86
Social functioning (SF-36) 75–80 83–86
Mental health (SF-36) 67–78 72–79
Depression (GHQ) 7.2 7.3
Anxiety (GHQ) 16a 14
SF-36, Short Form-36; high scores are favorable. GHQ, General Health Questionnaire; low scores are favorable.
a P  0.001; b P  0.01; differences from the normative data tested with Student t test (3, 5, 15) or Mann-Whitney U test (3, 5, 16, 25).
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Rasch model. A statistically nonsignificant probability value (P
0.05) indicates no substantial deviation from themodel. Individual
items or persons fit residual values of at least2.5, or probability
values below the Bonferroni adjusted -value are also used to in-
dicate misfit to the model.
Results
Literature review
Studies that addressed HRQoL explicitly in primary
adrenal insufficiency with validated questionnaires are
presented in Table 2; they reproducibly indicate reduced
vitality and general health perception and limitations in
physical and emotional functioning. Four large-scale sur-
veys undertaken by patient associations [The Nether-
lands, 1994 (P. Zelissen), n  91; UK1, 1997 (S. Baker,
personal communication), n 150;NorthAmerica, 1999
(P. Marquies and J. Miller), n 580; and UK2, 2006 (K.
White et al., personal communication), n  386] were
found and reviewed.Most of these were uncontrolled sur-
veys reporting various symptoms occurring frequently in
the patients, but essentially compliedwell with the picture
from the controlled studies. A few symptoms like heat
intolerance, sweating, thirst, waking in the night to pass
water, and gastrointestinal symptoms were frequently re-
ported in these surveys.
In-depth interviews
The interviews corroborated the reports of fatigue as
themost importantHRQoL issue inAddison’s disease but
showed great interindividual variation in symptoms.
Many felt a reduction in their physical endurance, but few
thought that Addison’s disease limited their physical
strength. Emotional stress was considered more problem-
atic than physical challenges. Some described altered so-
matic response to stress; they would stay calm in stressful
situations with a paradoxical decrease in heart rate. De-
pression and anxiety were not common in the interviewed
patients. Forgetfulness was a common concern among the
patients and their partners. Subjectively, Addison’s dis-
ease did not impose significant limitations for most of the
patients. Worries about adrenal crises were not particu-
larly common, but it would keep many from traveling to
remote areas without proper emergency care. Some
claimed to be healthier with Addison’s disease than they
would otherwise have been because theywould not let the
disease take control of their lives.
Item generation and item reduction
The consultation process with experts reduced the
number of items from 70 to 55 and added five more
items, yielding a preliminary questionnaire of 60 for the
TABLE 3. Thirty-six items included in the AddiQoL
questionnaire and the results of Rasch analysis of the
responses from 86 patients with Addison’s disease
Location
Fit
residual
P
value
I feel lightheaded 1.55 0.08 0.316
I get nauseous 1.29 0.05 0.518
I worry about my health 1.03 0.63 0.667
I find it difficult to think
clearly
1.01 0.20 0.020
I am happy 0.93 0.86 0.133
I feel low or depressed 0.63 0.08 0.419
I have to struggle to finish
jobs
0.59 1.95 0.049
I sweat for no particular
reason
0.57 3.45 0.011
I am irritable 0.54 0.27 0.053
My legs feel weak 0.53 0.01 0.587
I get headaches 0.51 2.48 0.194
I lose track of what I want
to say
0.49 0.34 0.802
I feel unwell first thing in
the morning
0.38 0.39 0.294
I can concentrate well 0.29 0.51 0.314
I have salt cravings 0.28 2.63 0.009
Normal daily activities make
me tired
0.13 1.12 0.102
My ability to work is limited 0.11 0.72 0.542
My joints and/or muscles
ache
0.10 0.29 0.355
I have back pain 0.08 0.80 0.425
I have to push myself to do
things
0.03 1.51 0.057
I feel good about my health 0.11 2.18 0.008
I sleep well 0.18 0.93 0.609
I am relaxed 0.44 0.21 0.880
I get ill more easily than
others
0.45 1.70 0.121
I feel physically fit 0.55 1.63 0.085
I have lost interest in sex 0.55 4.04 0.001
I need to get up during the
night to pass water
0.61 4.14 0.008
I can keep going during the
day without feeling tired
0.61 1.17 0.202
I feel rested when I wake
up in the morning
0.73 0.95 0.129
I am satisfied with my sex
life
0.78 3.29 0.126
I take a long time to
recover from illnesses
0.80 0.26 0.759
I put on weight easily 0.83 2.12 0.011
I cope well in emotional
situations
0.84 1.15 0.094
I have dry skin 0.92 2.59 0.043
Emotional stress makes me
exhausted
1.04 1.76 0.376
I feel full of energy 1.63 2.26 0.031
Location indicates hierarchical order of items; higher number reflects that
an item addresses higher level of HRQoL impairment. Fit residuals reflect
departure of the observed responses from the Rasch model; absolute fit
residuals  2.5 indicate lack of fit with a Rasch structure. P values
represent testing of fit to the Rasch model (2 statistics).
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pretesting in patients (Table 1S, published as supple-
mental data onThe Endocrine Society’s JournalsOnline
web site at http://jcem.endojournals.org). The scoring
by 100 patients of this preliminary 60-item question-
naire showed high internal consistency (Cronbach’s 
0.94). Aided by further statistical analyses as outlined
above and in Table 1S, the number of items was reduced
to 36.
Internal consistency and dimensional structure
The final 36-itemquestionnairewas completedby86of
100 patients. Their responses showed high internal con-
sistency as evaluated by Cronbach’s  0.95 and Person
separation index 0.94. Further Rasch analysis revealed
misfit to the Rasch model of the total 36 items, with item-
trait interaction 2  260 (P  0.0001). The item fit re-
siduals (Table 3) indicated departure of the observed
scores from the Rasch model, such that items with fit re-
siduals of at least 2.5 might not measure the same di-
mension as the total questionnaire. Exclusion of six items
with extreme fit residuals yielded satisfactory fit to the
Rasch model (item-trait interaction 2 141; P 0.09).
Figure 2 shows the distribution of patient locations
(spread in HRQoL) and item locations (spread in item
difficulty), indicating that the selection of items produces
a satisfactory coverage of spread in HRQoL for this par-
ticular patient group.The items locatedon the extreme left
of the graph are those easiest to endorse,whereas the items
on the extreme right are the most difficult to endorse. The
average mean person location of 0.355 suggests that the
scale was well-targeted for use in this group, with patients
on average a slightly higher level of HRQoL than the av-
erage of the scale items.
Discussion
Here,we present a newly developed, disease-specific ques-
tionnaire for assessment of HRQoL in Addison’s disease.
In endocrine disorders, disease-specific HRQoL question-
naires have become useful for both clinical management
and research in various contexts, such as GH replacement
therapy and tumor suppressive treatment in acromegaly
(18, 19). No questionnaire specific for adrenal insuffi-
ciency has as yet been formulated.
Previous studies of HRQoL in Addison’s disease and
the current in-depth interview study showed that fatigue,
i.e. reduced energy and vitality, is a major problem during
steroid replacement therapy. Previous studies also found
reduced role-emotional scores, or limitations due to emo-
tional problems (5, 15, 16); likewise, our clear impression
from the in-depth interviews was that impaired coping
with emotional stress is a salient feature of this disease.
Notably, among all the items we tested, the patients
scored worst on the item “Emotional stress makes me
exhausted.” Mental health issues were frequently re-
ported in the patient association surveys, and a recent reg-
istry-based study found increased prevalence of affective
disorders in patientswith adrenal insufficiency (24). Some
of the formal studies in Addison’s disease (16, 25), but not
all (5, 15), have found slightly impaired mental health
scores. Specifically, the patients scored worse than matched
controls on anxiety but not on depression (16). One clin-
ical trial showed beneficial effects of DHEA replacement
on sexuality in femaleswithadrenal insufficiency (primary
and secondary) (2), but this was not replicated in studies
thatonly includedAddison’sdiseasepatients (3, 5). In fact,
very little is known about sexuality and dysfunction in
patients with Addison’s disease on conventional treat-
FIG. 2. The person-item location distribution showing item locations (spread in difficulty) and person locations (spread in HRQoL), suggesting that
the scale was well-targeted for use in this group, with patients on average at a slightly higher level of HRQoL than the average of the scale items.
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ment. Forgetfulness was quite frequently reported in the
patient surveys and was also a concern expressed in the
in-depth interviews, although it was not found by formal
cognitive testing (3, 5). Formal questionnaire studies
found bodily pain scores normal (5, 15) or better than
normal (16), whereas the patient organization surveys re-
vealed frequentmuscle and joint pain. In the current study,
items addressing pain generally yielded positive scores (lit-
tle pain).
A comprehensive list of items was generated to cover
the issues above; some items were adapted from existing
questionnaires and others were newly formulated. A few
items addressed issues such as heat tolerance, sweating,
thirst, and nighttime urge to pass water, which had not
previously been tested in formal studies but which patient
surveys suggestedwere relevant.Weaddedbothpositively
and negatively worded phrasings to approach the issues
from different angles. We sought to select items that in-
dicate state as opposed to trait, because state ismore likely
to changewithin individuals in response to treatment (26).
The item reduction process was an iterative process using
clinical and statistical analyses.After the process and anal-
yses described here, we have developed a questionnaire
thatmaintains a highdegree of internal consistency aswell
as a satisfactory breadth of coverage ofHRQoL issues and
also targets the patient population very well.
Further validation studies in larger populations are
needed to verify and explore the dimensional structure of
AddiQoL and to determine test-retest reliability and its
validity as a tool formeasurementof treatment effects.The
questionnaire will be translated into other languages for
cross-cultural validation. The patients in our study did
volunteer via a patient organization, such that some
selection bias in their responses cannot be excluded.
Further Rasch analysis of the responses in several uns-
elected patient and control populations is required to
determine its psychometric properties and to develop
scoring algorithms.
In conclusion,weenvisage this novelAddison’sdisease-
specific questionnaire (AddiQoL) having utility in trials of
hormone replacement and management of patients with
Addison’s disease, analogous to questionnaires in GH de-
ficiency (AGHDA) and acromegaly (AcroQoL).
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